Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Jensen

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
American Heart Journal|March 9, 2026
Empagliflozin and Functional Aerobic Capacity in Individuals with Increased Risk of Heart Failure: The Empire Prevent Cardiac TrialJulie H Larsen, Camilla F Andersen, Mathilde Mb Jessen, et al.
Journal of Cardiac Failure|March 14, 2026
The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac TrialJulie Hempel Larsen, Camilla Fuchs Andersen, Maria Callesen Hansen, et al.
European Journal of Preventive Cardiology|January 8, 2026
Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic TrialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
American Heart Journal|May 5, 2022
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trialJesper Jensen, Massar Omar, Mulham Ali, et al.
Cardiovascular Diabetology|June 13, 2026
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
The Lancet. Diabetes & Endocrinology|December 28, 2020
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
American Heart Journal|August 18, 2020
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
European Journal of Heart Failure|November 15, 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trialCamilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
Cardiovascular Diabetology|August 2, 2025
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort studyAbdullahi Ahmed Mohamed, Camilla Fuchs Andersen, Daniel Mølager Christensen, et al.
Kidney360|January 17, 2023
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD TrialKatja Vu Bartholdy, Niklas Dyrby Johansen, Nino Landler, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
American Heart Journal|March 9, 2026
Empagliflozin and Functional Aerobic Capacity in Individuals with Increased Risk of Heart Failure: The Empire Prevent Cardiac TrialJulie H Larsen, Camilla F Andersen, Mathilde Mb Jessen, et al.
Journal of Cardiac Failure|March 14, 2026
The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac TrialJulie Hempel Larsen, Camilla Fuchs Andersen, Maria Callesen Hansen, et al.
European Journal of Preventive Cardiology|January 8, 2026
Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic TrialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
American Heart Journal|May 5, 2022
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trialJesper Jensen, Massar Omar, Mulham Ali, et al.
Cardiovascular Diabetology|June 13, 2026
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
The Lancet. Diabetes & Endocrinology|December 28, 2020
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
American Heart Journal|August 18, 2020
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trialJesper Jensen, Massar Omar, Caroline Kistorp, et al.
European Journal of Heart Failure|November 15, 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trialCamilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
Cardiovascular Diabetology|August 2, 2025
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort studyAbdullahi Ahmed Mohamed, Camilla Fuchs Andersen, Daniel Mølager Christensen, et al.
Kidney360|January 17, 2023
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD TrialKatja Vu Bartholdy, Niklas Dyrby Johansen, Nino Landler, et al.
Pageof 8